Dr. Brian L. Johnson, MD
Mohs Surgery (MOHS-Micrographic Surgery Physician)
5630 Lowery Rd
Norfolk, VA 23502
Who else practices at this address →
Norfolk city is a federal dental shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Uniformed Services Uhs Fe Hebert School of Med (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,201
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Uniformed Services Uhs Fe Hebert School of Med
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
MOHS-Micrographic Surgery Physician primary
VA license 0101042937 · GA license 048364 -
Clinical & Laboratory Dermatological Immunology Physician
GA license 048364 -
Dermatology Physician
GA license 048364 · VA license 0101042937 -
Dermatopathology Physician
GA license 048364 -
General Practice Physician
GA license 048364 -
Pediatric Dermatology Physician
GA license 049364 -
Procedural Dermatology Physician
GA license 048364
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sentara Obici Hospital Suffolk, VA
Medical groups
- Anne Arundel Dermatology PA (127 clinicians)
- Georgia Dermatology and Skin Cancer Center, LLC (53 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,201
- Services billed
- 3,228
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 1,079 | 875 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 445 | 338 |
| Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | 172 | 153 |
| Established patient office or other outpatient visit, 10-19 minutes | 164 | 122 |
| Established patient office or other outpatient visit, 20-29 minutes | 137 | 124 |
| Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | 92 | 90 |
| Destruction of precancer skin growth, 2-14 growths | 90 | 20 |
| Biopsy of related skin growth, first growth | 77 | 70 |
| New patient office or other outpatient visit, 30-44 minutes | 74 | 74 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 58 | 55 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Doxycycline Monohydrate Other prescribers in Norfolk, VA | 130 |
| Clobetasol Propionate Other prescribers in Norfolk, VA | 21 |
| Ibuprofen Other prescribers in Norfolk, VA | 20 |
| Fluorouracil Other prescribers in Norfolk, VA | 16 |
| Triamcinolone Acetonide Other prescribers in Norfolk, VA | 16 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Norfolk, VA | 14 |
| Tramadol Hcl Other prescribers in Norfolk, VA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 37 payments worth $782 in total to this clinician.
| AbbVie Inc. | $339 |
|---|---|
| Janssen Biotech, Inc. | $264 |
| Janssen Scientific Affairs, LLC | $82.99 |
| Regeneron Healthcare Solutions, Inc. | $60.05 |
| Galderma Laboratories, L.P. | $18.93 |
| Leo Pharma Inc. | $17.54 |
| Food and Beverage | $782 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 5 companies. The companies reported $386,695 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc. - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Completed · NCT06130566 - Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Sanofi US Services Inc. · Active, not recruiting · NCT05492578 - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
Janssen Research & Development, LLC - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized …
Janssen Research & Development, LLC - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Sanofi US Services Inc. · Active, not recruiting · NCT06241118 - A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outp…
Amgen Inc. - A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
Genzyme Corporation · Active, not recruiting · NCT05206773 - A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis …
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.